Edesa Biotech is trading at $2.58 (+20.56%) in pre-market after its Japanese partner KYORIN announced an exclusive license for EB05 on November 9. - EB05 is Edesa Biotechβs ARDS treatment candidate. The deal includes a $12 million upfront payment, up to $134 million in milestones, and royalties. - The broader market is also higher pre-market, but the licensing agreement is the most direct explanation for the move.